Capacity Analysis for Viral Vector Manufacturing: Is There Enough?

LBG’s Dr. Joseph Rininger, Dr. Ashley Fennell, Dr. Lauren Schoukroun-Barnes, Christopher Peterson and Dr. Joshua Speidel recently published a joint article titled, Capacity Analysis for Viral Vector Manufacturing: Is There Enough?.  

The article discusses the increasing demand for viral vectors and whether CDMO capacity is keeping pace with demand. By using a model built to forecast the quantity of viral vectors required to support ongoing and planned clinical trials, the authors suggest that demand will exceed CDMO manufacturing capacity by Q1 2020. 

A must-read if you are in the Viral Vector Manufacturing arena. 

For more information on the findings or how we can support your specific needs email us at or set up an appointment with one of our team members here.